|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| OPERATING ACTIVITIES: | |||||
| Net income (loss) | |||||
| Net earnings from discontinued operations, net of income taxes | |||||
| Adjustments to reconcile net income (loss) to cash flows provided by operating activities: | |||||
| Realized losses on investments | |||||
| Total realized losses on investments | |||||
| Unrealized (gains) losses on investments | |||||
| Realized losses (gains) on investments | |||||
| Fair value changes in trading securities, funds held and other investments | |||||
| Goodwill impairment | |||||
| Amortization of net deferred charge assets | |||||
| Depreciation, accretion and other amortization | |||||
| Net gain on Enhanzed Re novation | |||||
| Losses (income) from equity method investments | |||||
| Other adjustments | |||||
| Changes in: | |||||
| Reinsurance balances recoverable on paid and unpaid losses | |||||
| Losses and loss adjustment expenses | |||||
| Defendant asbestos and environmental liabilities | |||||
| Insurance and reinsurance balances payable | |||||
| Other operating assets and liabilities | |||||
| Funds held | |||||
| Cash consideration for the Enhanzed Re novation | |||||
| Sales and maturities of trading securities | |||||
| Purchases of trading securities | |||||
| Payments to cover securities sold short | |||||
| Proceeds from securities sold short | |||||
| Net payments for derivative contracts | |||||
| Net gain on purchase and sales of subsidiaries | |||||
| Net cash flows provided by operating activities | |||||
| Total net cash flows provided by operating activities | |||||
| INVESTING ACTIVITIES: | |||||
| Sales and maturities of available-for-sale securities | |||||
| Purchase of available-for-sale securities | |||||
| Sale of subsidiary | |||||
| Purchase of other investments | |||||
| Proceeds from other investments | |||||
| Proceeds from the sale of equity method investments | |||||
| Acquisition, net of cash acquired | |||||
| Sales of subsidiaries, net of cash previously held | |||||
| Other | |||||
| Consolidation of the InRe Fund opening cash and restricted cash balances (Note 15) | |||||
| Variable Interest Entity, Primary Beneficiary | |||||
| Total consolidation of the InRe Fund opening cash and restricted cash balances (Note 15) | |||||
| Net cash flows provided by (used in) investing activities | |||||
| Total net cash flows provided by (used in) investing activities | |||||
| FINANCING ACTIVITIES: | |||||
| Dividends on preferred shares | |||||
| Dividends paid to noncontrolling interests | |||||
| Acquisition of noncontrolling and redeemable noncontrolling shareholders’ interests in subsidiaries | |||||
| Repurchase of shares | |||||
| Issuance of debt, net of issuance costs | |||||
| Repayment of debt | |||||
| Net cash flows used in financing activities | |||||
| Net cash flows provided by operating activities | |||||
| Net cash flows used in investing activities | |||||
| Net cash flows from discontinued operations | |||||
| EFFECT OF EXCHANGE RATE CHANGES ON FOREIGN CURRENCY CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||
| NET CHANGE IN CASH OF BUSINESSES HELD-FOR-SALE | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR | |||||
| Non-cash operating activities: | |||||
| Novation of future policy holder benefits | |||||
| Funds held directly managed transferred in exchange on novation of future policy holder benefits | |||||
| Other assets / liabilities transferred on novation of future policy holder benefits | |||||
| Losses and loss adjustment expenses transferred in connection with settlement of participation in Atrium's Syndicate 609 | |||||
| Investments transferred in connection with settlement of participation in Atrium's Syndicate 609 | |||||
| Non-cash investing activities: | |||||
| Unsettled purchases of available-for-sale securities and other investments | |||||
| Unsettled sales of available-for-sale securities and other investments | |||||
| Receipt of available-for-sale securities as consideration in exchange for assumption of reinsurance contract liabilities | |||||
| Receipt of available-for-sale debt securities as consideration in exchange for assumption of liabilities | |||||
| Removal of equity method investment relating to acquisition of a subsidiary | |||||
| Receipt of other investments as consideration | |||||
| Contribution to other investments | |||||
| Redemption of other investments | |||||
| Reduction in investment fees | |||||
| Purchase of equity method investment through acquisition of subsidiary | |||||
| AFS securities received as consideration for assumption of liabilities | |||||
| Redemption of NCI | |||||
| Non-cash financing activities: | |||||
| Settlement of loan receivable as partial consideration for RNCI redemption | |||||
| Transfer of equity interest in Northshore as partial consideration for RNCI redemption | |||||
| Distributions to redeemable noncontrolling interests | |||||
| Increase in noncontrolling interests due to the acquisition of a subsidiary | |||||
| Third-party capital withdrawal from the InRe Fund through transfer of trading security | |||||
| Supplemental Cash Flow Information: | |||||
| Income taxes (received) paid, net of refunds | |||||
| Interest paid | |||||
| Reconciliation to Consolidated Balance Sheets: | |||||
| Cash and cash equivalents | |||||
| Variable Interest Entity, Primary Beneficiary | |||||
| Total cash and cash equivalents | |||||
| Restricted cash and cash equivalents | |||||
Loading...